ClinicalTrials.gg
RecruitingNCT06672523Updated Jun 8, 2026

A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

A Phase 1 interventional study of BMS-986504 and [14C]-BMS-986504 in Advanced Solid Tumors With Homozygous MTAP Deletion, sponsored by Bristol-Myers Squibb. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the mass balance, metabolism, elimination, and drug levels of [14C]-BMS-986504 (MRTX1719) in participants with advanced solid tumors with homozygous methylthioadenosine phosphorylase deletion.

02

Conditions studied

  • Advanced Solid Tumors With Homozygous MTAP Deletion

Keywords

  • Protein arginine methyltransferase (PRMT5)
  • Methylthioadenosine-cooperative PRMT5 inhibitor
  • Homozygous methylthioadenosine phosphorylase (MTAP) deletion
  • Mass balance study
  • Metabolism
  • Elimination
  • Drug absorption
  • Distribution
  • Excretion
  • Radiolabeled
  • Absorption, distribution, metabolism, and excretion (ADME)
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have an advanced, unresectable, or solid tumor with a deletion of the methylthioadenosine phosphorylase (MTAP) gene.
  • Participants must have received, be to, be ineligible for, or be intolerant of available standard care for their cancer.

Exclusion criteria

Exclusion Criteria

  • Participants must not have a history of any surgical or medical conditions possibly affecting how the study drug is distributed, broken down (metabolized) and removed (excreted or eliminated) from the body.
  • Participants must not have participated in a clinical study involving a radiolabeled study drug within 12 months prior to admission to the research center.
  • Participants must not have a current or recent (within 3 months of study drug administration) gastrointestinal disease.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    [14C]-BMS-986504 followed by BMS-986504 Monotherapy

    Part A: Participants will receive a single oral dose of radiolabeled \[14C\]-BMS-986504 on C1D1. Part B: Participants will receive non-radiolabeled BMS-986504, starting from C1D1 and until criteria for treatment discontinuation are met.

    Drug: BMS-986504 · Drug: [14C]-BMS-986504

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax)

    Time frame: Up to 2 weeks

  2. Time of maximum observed drug concentration (Tmax)

    Time frame: Up to 2 weeks

  3. Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))

    Time frame: Up to 2 weeks

  4. Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))

    Time frame: Up to 2 weeks

  5. Terminal elimination half-life (T-HALF)

    Time frame: Up to 2 weeks

  6. Apparent total body clearance (CLT/F)

    Time frame: Up to 2 weeks

  7. Apparent volume of distribution during the terminal phase (Vz/F)

    Time frame: Up to 2 weeks

  8. Percentage of estimated part for the calculation of AUC(INF) (%AUC(INF))

    Time frame: Up to 2 weeks

  9. Blood-to-plasma total radioactivity (TRA) ratio

    Time frame: Up to 2 weeks

  10. Total amount of administered dose recovered in urine (UR)

    Time frame: Up to 2 weeks

  11. Percent of administered dose recovered in urine (%UR)

    Time frame: Up to 2 weeks

  12. Renal clearance (CLR) in urine

    Time frame: Up to 2 weeks

  13. Total radioactivity in UR

    Time frame: Up to 2 weeks

  14. Total radioactivity in %UR

    Time frame: Up to 2 weeks

  15. Total radioactivity in total amount of administered dose recovered in feces (FR)

    Time frame: Up to 2 weeks

  16. Total radioactivity in percent of administered dose recovered in feces (%FR)

    Time frame: Up to 2 weeks

  17. Total amount of radioactivity recovered (Rtotal)

    Time frame: Up to 2 weeks

  18. Total percent of radioactivity recovered (%TOTAL)

    Time frame: Up to 2 weeks

  19. TRA amount recovered and fraction of the radioactive dose in vomit if applicable

    Time frame: Up to 2 weeks

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 2 years

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 2 years

  3. Number of participants with AEs leading to discontinuation

    Time frame: Up to 2 years

  4. Number of participants with drug-related AEs

    Time frame: Up to 2 years

  5. Number of participants with laboratory abnormalities

    Time frame: Up to 2 years

  6. Number of deaths

    Time frame: Up to 2 years

07

Study locations

3 of 3 sites recruiting
  • ICON / PRA Magyarország Kft. Fázis I-es Klinikai Farmakológiai Vizsgálóhely
    Budapest, 1076, Hungary
    Recruiting
    • Zsuzsanna Papai, Site 0001 · Contact+36308281059
  • START Rioja, The START Center for cancer research
    Logroño, 26006, Spain
    Recruiting
    • Maria De Miguel, Site 0004 · Contact+34955013068
  • Centro Integral Oncologico Clara Campal-Hospital HM Universitario Sanchinarro-START Madrid,
    Madrid, 28050, Spain
    Recruiting
    • Irene Moreno Candilejo, Site 0003 · Contact917567800
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Oct 2027, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2024
First posted
Nov 4, 2024
StartActual
Mar 24, 2025
Primary completionEst.
Oct 25, 2027
CompletionEst.
Oct 25, 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06672523
Responsible party
Sponsor
First posted
Nov 4, 2024
Start date
Mar 24, 2025
Primary completion
Oct 25, 2027 (estimated)
Completion
Oct 25, 2027 (estimated)
Last update
Jun 8, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Navlimetostat

Start the discussion